Anti-vimentin antibodies and neuron-specific enolase in children with neurofibromatosis type-1

Neuroendocrinology Letters

Volumn 28, Issue 6, 2007, Pages 761-764

  Kotaška, Karel ^a   Petrak, Borivoj ^a   Kukacka, Jiri ^a   Kraus, Josef ^a   Prusa, Richard ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Anti vimentin; Children; Neurofibromatosis type 1; NSE

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEURON SPECIFIC ENOLASE; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIMENTIN ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMA; NEUROFIBROMATOSIS; OPTIC NERVE GLIOMA; SENSITIVITY AND SPECIFICITY;

EID: 37849029612     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Ferrari S, Cannizzaro LA, Battini R, Huebner K, Baserga R. The gene encoding human vimentin is located on the short arm of chromosome 10. Am. J. Hum. Genet 1987; 41: 616-626.
2. Huson SM, Harper PS, Compston DAS. Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales. Brain 1989; 11: 1355-1381.
3. Kaiserling E, Ruck P, Handgretinger R, Leipoldt M, Hipfel R. Immunohistochemical and cytogenetic findings in malignant rhabdoid tumor. Gen Diagn Pathol 1996;141(5-6): 327-337.
4. Kotaska K, Petrak B, Kukacka J, Prusa R. Anti-vimentin antibodies and NSE in children with neurofibromatosis. Clin Chem 2006; 52 (Suppl.6): A35-A36.
5. Kukacka J, Vajtr D, Huska D, Prusa R, Houstava L, Samal F, Diopan V, Kotaska K, Kizek R.: Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury. Neuroendocrinol Lett. 2006;27(Suppl 2):116-120.
6. Lauga F, Kress C, Colucci-Guyon E, Khun H, Vandormael-Pourin S, Huerre M,Babinet C. Teratocarcinomas induced by embryonic stem (ES) cells lacking vimentin: an approach to study the role of vimentin in tumorogenesis. J Cell Sci 2000; 113(19): 3463-3472.
7. Lukacs A, Junk AK, Stefani FH, Kampik A, Schirren CG, Plewig G. Lisch nodules. Markers of neurofibromatosis 1 and immunohistochemical references for neuroectodermal differentiation. Hauptarzt 1997; 48(1):38-41.
8. NIH Consensus Development Conference Statement Neurofibromatosis conference statement. Arch Neurol 1988; 45: 575-578.
9. Otsuka F, Kawashima T, Imakado S, Usuki Y, Honmura S. Lisch nodules and skin manifestation in neurofibromatosis type 1. Arch Derm 2001; 137: 232-233.
10. Pieper FR, Schaart G, Krimpenfort PJ, Henderik JB, Mosha A, Ramaekers, FR et al. Transgenic expression of the muscle-specific filament protein desmin in nonmuscle cells. J Cell Biol 1989; 108(3): 1009-1024.
11. Riccardi VM. Malignancy. In: Richardi VM, editor. Neurofibromatosis, phenotype, natural history and pathogenesis. Baltimore; John Hopkins University Press, 1992; 213-223.
12. Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004;111: 568-577.
13. Zoeller MET, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and Benign tumors in Patients with Neurofibromatosis type 1 in a Defined Swedish Population. Cancer 1997; 79 (11): 2125-2130.